Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Matthew Klein
AddedMar 19, 2024
UpdatedMay 31, 2026
Matthew Klein

Matthew Klein

Board Member, ClearPoint Neuro

CrunchbaseLinkedIn

Matthew Klein's Career

ClearPoint Neuro
ClearPoint Neuro

Solana Beach, CA, US

Board Member· Board
PTC Therapeutics
PTC Therapeutics

South Plainfield, NJ, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Matthew Klein's Career

ClearPoint Neuro
ClearPoint Neuro
Public$130.4M1081998Solana Beach, CA, US
Board Member· Board

Leadership at ClearPoint Neuro

Joe BurnettJoe BurnettCEO
Lynnette FallonLynnette FallonBoard Member
Paul A. BottomleyPaul A. BottomleyCo-Founder
Lennart LindLennart LindCo-Founder
Kathleen WilsonKathleen WilsonCo-Founder
PTC Therapeutics
PTC Therapeutics
Public$1.6B1.4k1998South Plainfield, NJ, US
CEO· C-Suite · Management

Leadership at PTC Therapeutics

Emma ReeveEmma ReeveBoard Member
David SouthwellDavid SouthwellBoard Member
Glenn D. SteeleGlenn D. SteeleBoard Member
Stuart W. PeltzStuart W. PeltzBoard Member
Stuart PeltzStuart PeltzCo-Founder
Jerome B. ZeldisJerome B. ZeldisBoard Member

Similar to PTC Therapeutics

Amicus TherapeuticsAmicus TherapeuticsCranbury, NJ, USBiopharmaceuticalsest. 2002Amicus TherapeuticsCranbury, NJ, US · est. 2002

Amicus Therapeutics, a US-based public biopharmaceutical company, specializes in innovative medical solutions.

Public · $2.4B484
Sarepta TherapeuticsSarepta TherapeuticsCambridge, MA, USGene Therapiesest. 1980Sarepta TherapeuticsCambridge, MA, US · est. 1980

Sarepta Therapeutics, a US-based biopharmaceutical firm, specializes in medical research and drug development.

Public · $1.4B1.2k
BioCryst PharmaceuticalsBioCryst PharmaceuticalsDurham, NC, USPharmaceuticalsest. 1986BioCryst PharmaceuticalsDurham, NC, US · est. 1986

BioCryst Pharmaceuticals: A global biotech firm innovating oral treatments for rare diseases.

Public · $1.8B531
United TherapeuticsUnited TherapeuticsSilver Spring, MD, USPharmaceuticalsest. 1996United TherapeuticsSilver Spring, MD, US · est. 1996

United Therapeutics, a Maryland-based biotech firm, develops pharmaceuticals for vascular diseases using synthetic prostacyclin.

Public985

Matthew Klein's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJaeHong ChoiJaeHong ChoiBoard Member · KakaoMason YeoMason YeoBoard Member · Kakao

People Similar to Matthew Klein

Matthew WolfsonMatthew WolfsonBoard Member · Electromedical TechnologiesKen ChaplinKen ChaplinBoard Member · DoximityReza MalekReza MalekBoard Member · EmboMedicsSteve CorneliusSteve CorneliusBoard Member · BiolectricsChris LeongChris LeongBoard Member · NestléJonathan MurrayJonathan MurrayCo-Founder · Lynq